BIOTECHNOLOGY VALUE FUND L P 4
4 · Kymera Therapeutics, Inc. · Filed Jun 25, 2026
Research Summary
AI-generated summary of this filing
Kymera (KYMR) BVF Partners Receives 6,068-Share Award
What Happened
- BVF Partners L.P. (part of a group of reporting entities and tied to a director on Kymera’s board) was reported as receiving an award of 6,068 derivative shares in Kymera Therapeutics (KYMR) on 2026-06-24. The transaction is reported as an award/grant (code A) with an acquisition price of $0.00, so no cash was paid on filing. The filing indicates these are derivative securities (e.g., options/awards) rather than an open-market purchase.
Key Details
- Transaction date: 2026-06-24; Form 4 filed 2026-06-25 (timely filing).
- Transaction type/code: Award/Grant (A); derivative securities acquired at $0.00.
- Amount: 6,068 shares acquired; reported value $0 on the Form 4.
- Shares owned after transaction: not specified in the provided filing extract.
- Notable footnotes: the Form 4 is filed jointly by several BVF entities and Mark Lampert (Section 13(d) group) and disclaims direct beneficial ownership except to the extent of pecuniary interest (see footnotes). A board member, Gorjan Hrustanovic, is involved and has agreed to transfer any economic benefit from the shares to Partners. Vesting/derivative details are referenced in the footnotes (some awards reference vesting schedules; the filing also includes a note that certain shares subject to an option have fully vested).
- Transaction code meaning: A = Award/Grant. This is a derivative award, not an open-market buy or sale.
Context
- This is an institutional/investor-group award tied to a board member’s arrangement with BVF, not a direct cash purchase or sale by an individual executive. For retail investors, awards at $0 often reflect compensation or investment arrangements and do not necessarily signal immediate buying conviction. The derivative nature means cash was not exchanged at filing; check future filings for exercises or sales.
Insider Transaction Report
Form 4
BVF PARTNERS L P/IL
DirectorOther
Transactions
- Award
Stock Option (Right to Buy)
[F6][F7]2026-06-24+6,068→ 6,068 total(indirect: See footnote)Exercise: $99.87Exp: 2036-06-23→ Common Stock, $0.0001 par value (6,068 underlying)
Holdings
- 2,798,795
Common Stock, $0.0001 par value
[F1][F2] - 2,219,858
Common Stock, $0.0001 par value
[F1][F3] - 353,412
Common Stock, $0.0001 par value
[F1][F4] - 130,645(indirect: See footnote)
Common Stock, $0.0001 par value
[F1][F5] - 201,546
Pre-Funded Warrants to Purchase Common Stock
[F1][F8][F2]Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying) - 156,742
Pre-Funded Warrants to Purchase Common Stock
[F1][F8][F3]Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying) - 550,425
Pre-Funded Warrants to Purchase Common Stock
[F1][F8][F2]Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying) - 375,856
Pre-Funded Warrants to Purchase Common Stock
[F1][F8][F3]Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying) - 52,733
Pre-Funded Warrants to Purchase Common Stock
[F1][F8][F4]Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying) - 27,797(indirect: See footnote)
Pre-Funded Warrants to Purchase Common Stock
[F1][F8][F5]Exercise: $0.00→ Common Stock, $0.0001 par value (27,797 underlying) - 40,127(indirect: See footnote)
Stock Option (Right to Buy)
[F6][F9]Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying) - 20,063(indirect: See footnote)
Stock Option (Right to Buy)
[F6][F9]Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying) - 12,000(indirect: See footnote)
Stock Option (Right to Buy)
[F6][F9]Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying) - 12,000(indirect: See footnote)
Stock Option (Right to Buy)
[F6][F9]Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying) - 16,000(indirect: See footnote)
Stock Option (Right to Buy)
[F6][F9]Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying) - 16,000(indirect: See footnote)
Stock Option (Right to Buy)
[F6][F9]Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying)
Footnotes (9)
- [F4]Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
- [F1]This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- [F2]Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- [F3]Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- [F5]Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account.
- [F6]Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- [F7]The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.
- [F8]The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.
- [F9]The shares subject to the option have fully vested.